-
1.发明授权公开(公告)号：US11426397B2
公开(公告)日：2022-08-30
申请号：US16497967
申请日：2018-03-26
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Jason Green , Maria Hopkins , Benjamin Jones , Andre A. Kiryanov , Jon Kuehler , Holger Monenschein , Sean Murphy , Thomas Nixey , Huikai Sun
IPC: C07D417/12 , A61K31/4545 , A61K31/198 , A61K31/451 , A61K31/4525 , A61K31/4535 , A61K31/454 , A61K31/496 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/5365 , A61K31/553 , C07D211/52 , C07D401/12 , C07D401/14 , C07D405/12 , C07D409/12 , C07D413/12 , C07D487/04 , C07D498/04
Abstract: Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R4, R5, R8, R10, R11, X1, X2, X3, X9, X12, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.
-
公开(公告)号：US10407409B2
公开(公告)日：2019-09-10
申请号：US15909801
申请日：2018-03-01
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Jason W. Brown , Melinda Davis , Anthony Ivetac , Benjamin Jones , Andre A. Kiryanov , Jon Kuehler , Marion Lanier , Joanne Miura , Sean Murphy , Xiaolun Wang
IPC: C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , A61K31/4439 , A61K31/4545 , A61K31/5377 , A61K31/496 , A61K31/551 , C07D491/107 , C07D471/08 , C07D487/06 , C07D487/10 , C07D491/10 , A61K31/444 , A61K31/4985 , A61K31/5513 , C07D487/04
Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
-
公开(公告)号：US09434743B2
公开(公告)日：2016-09-06
申请号：US14378305
申请日：2013-02-28
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Zacharia Cheruvallath , Philip Erickson , Jun Feng , Mallareddy Komandla , John David Lawson , Christopher McBride , Joanne Miura , Sean Murphy , Mingnam Tang , Huong-Thu Ton-Nu
IPC: C07D498/04 , C07D401/04 , C07D471/04 , C07D403/04 , C07D405/04 , C07D417/04 , C07D487/04 , C07D401/14 , C07D413/14 , C07D231/56 , C07D403/10 , C07D407/14 , C07D413/04 , C07D413/10 , A61K31/416 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06
CPC classification number: C07D498/04 , A61K31/416 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07D231/56 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D407/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
-
公开(公告)号：US09040522B2
公开(公告)日：2015-05-26
申请号：US14226722
申请日：2014-03-26
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Jason W. Brown , Melinda Davis , Anthony Ivetac , Benjamin Jones , Andre A. Kiryanov , Jon Kuehler , Marion Lanier , Joanne Miura , Sean Murphy , Xiaolun Wang
IPC: A61K31/496 , A61K31/551 , C07D401/04 , C07D401/14 , C07D491/107 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D487/06 , C07D487/10 , C07D491/10
CPC classification number: C07D401/14 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/551 , A61K31/5513 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D487/04 , C07D487/06 , C07D487/10 , C07D491/10 , C07D491/107
Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD and pharmaceutical compositions thereof.
Abstract translation: 本发明提供下式的化合物：其可用作PHD的抑制剂及其药物组合物。
-
公开(公告)号：US20150005232A1
公开(公告)日：2015-01-01
申请号：US14378305
申请日：2013-02-28
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Zacharia Cheruvallath , Philip Erickson , Jun Feng , Mallareddy Komandla , John David Lawson , Christopher McBride , Joanne Miura , Sean Murphy , Mingnam Tang , Huong-Thu Ton-Nu
IPC: C07D498/04 , A61K31/416 , A61K45/06 , C07D401/04 , A61K31/4439 , C07D471/04 , A61K31/437 , A61K31/5383 , C07D403/04 , A61K31/506 , C07D405/04 , C07D413/10 , A61K31/4245 , C07D417/04 , A61K31/427 , C07D401/14 , A61K31/5377 , C07D487/04 , A61K31/53 , C07D231/56
CPC classification number: C07D498/04 , A61K31/416 , A61K31/4245 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/506 , A61K31/53 , A61K31/5377 , A61K31/5383 , A61K45/06 , C07D231/56 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/10 , C07D405/04 , C07D407/14 , C07D413/04 , C07D413/10 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, and R6 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating obesity and related diseases, disorders, and conditions associated with MetAP2.
Abstract translation: 公开了式1的化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5和R 6在本说明书中定义。 本公开还涉及用于制备式1化合物的材料和方法，含有它们的药物组合物及其用于治疗与MetAP2相关的肥胖症和相关疾病，病症和病症的用途。
-
Patent Agency Ranking
6.发明申请公开(公告)号：US20200375969A1
公开(公告)日：2020-12-03
申请号：US16497967
申请日：2018-03-26
Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventor： Jason Green , Maria Hopkins , Benjamin Jones , Andre A. Kiryanov , Jon Kuehler , Holger Monenschein , Sean Murphy , Thomas Nixey , Huikai Sun
IPC: A61K31/4545 , A61K31/198 , A61K31/454 , A61K31/451 , A61K31/506 , A61K31/4525 , A61K31/496 , A61K31/553 , A61K31/4535 , A61K31/519 , A61K31/501 , A61K31/5365 , C07D401/12 , C07D211/52 , C07D401/14 , C07D405/12 , C07D498/04 , C07D413/12 , C07D409/12 , C07D487/04 , C07D417/12
Abstract: Disclosed are compounds of Formula 1 and pharmaceutically acceptable salts thereof, wherein L, R4, R5, R8, R10, R11, X1, X2, X3, X9, X12, and Z are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with GPR6.
-
公开(公告)号：US09708296B2
公开(公告)日：2017-07-18
申请号：US15150976
申请日：2016-05-10
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Jason W. Brown , Melinda Davis , Anthony Ivetac , Benjamin Jones , Andre A. Kiryanov , Jon Kuehler , Marion Lanier , Joanne Miura , Sean Murphy , Xiaolun Wang
IPC: C07D401/14 , C07D405/14 , C07D413/14 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/5377 , A61K31/496 , A61K31/551 , C07D401/04 , C07D491/107 , C07D417/14 , C07D471/08 , C07D487/06 , C07D487/10 , C07D491/10 , A61K31/4545 , A61K31/4985 , A61K31/5513 , C07D487/04
CPC classification number: C07D401/14 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/551 , A61K31/5513 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D487/04 , C07D487/06 , C07D487/10 , C07D491/10 , C07D491/107
Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
-
公开(公告)号：US20180186772A1
公开(公告)日：2018-07-05
申请号：US15909801
申请日：2018-03-01
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Jason W. Brown , Melinda Davis , Anthony Ivetac , Benjamin Jones , Andre A. Kiryanov , Jon Kuehler , Marion Lanier , Joanne Miura , Sean Murphy , Xiaolun Wang
IPC: C07D401/14 , A61K31/496 , C07D487/06 , A61K31/4985 , A61K31/5513 , C07D491/107 , C07D405/14 , C07D471/08 , C07D401/04 , A61K31/4545 , C07D487/10 , A61K31/444 , A61K31/551 , C07D491/10 , A61K31/5377 , C07D417/14 , C07D413/14 , C07D487/04
CPC classification number: C07D401/14 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/551 , A61K31/5513 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D487/04 , C07D487/06 , C07D487/10 , C07D491/10 , C07D491/107
Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
-
公开(公告)号：US20200277262A1
公开(公告)日：2020-09-03
申请号：US16650858
申请日：2018-09-24
Applicant: Benjamin Jones , Andre Kiryanov , Jon Kuehler , Marion Lanier , Sean Murphy , Feng Zhou , Takeda Pharmaceutical Company Limited
Inventor： Benjamin Jones , Andre Kiryanov , Jon Kuehler , Marion Lanier , Sean Murphy , Feng Zhou
IPC: C07D213/81
Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein R3, R4, R5, R6, R7, R8, R9, X1 and X2 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with PHD.
-
公开(公告)号：US09944626B2
公开(公告)日：2018-04-17
申请号：US15620620
申请日：2017-06-12
Applicant: Takeda Pharmaceutical Company Limited
Inventor： Jason W. Brown , Melinda Davis , Anthony Ivetac , Benjamin Jones , Andre A. Kiryanov , Jon Kuehler , Marion Lanier , Joanne Miura , Sean Murphy , Xiaolun Wang
IPC: C07D413/14 , A61K31/5377 , C07D401/14 , C07D487/06 , C07D417/14 , C07D491/10 , A61K31/551 , A61K31/444 , C07D487/10 , A61K31/4545 , C07D401/04 , C07D471/08 , C07D405/14 , C07D491/107 , A61K31/5513 , A61K31/4985 , C07D487/04 , A61K31/496
CPC classification number: C07D401/14 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/4985 , A61K31/5377 , A61K31/551 , A61K31/5513 , C07D401/04 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D487/04 , C07D487/06 , C07D487/10 , C07D491/10 , C07D491/107
Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.054 seconds)
